For research use only
| Cat No. | ABC-TC0115 |
| Product Type | Human Ovarian Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Ovary |
| Disease | Adenocarinoma |
| Product Code | CaOv-4; CaOV-4; CAOV-4; CAOV4; Caov4 |
The Caov-4 cell line is derived from human ovarian adenocarcinoma and used in epithelial ovarian cancer drug screening and biomarker analysis.
Caov-4 is a human epithelial ovarian adenocarcinoma cell line originally derived from the ovaries of a 45-year-old Caucasian female patient diagnosed with ovarian serous adenocarcinoma. It exhibits epithelial-like morphology and forms adherent monolayers under standard culture conditions. Cytogenetic analysis reveals a near-triploid karyotype with multiple structural abnormalities, and the cell line displays mutations and aberrations typical of high-grade serous ovarian cancers, including alterations in TP53 signaling pathways. Caov-4 expresses moderate levels of epithelial markers such as cytokeratin and E-cadherin and is negative for estrogen (ER) and progesterone receptors (PR). The cell line is tumorigenic in immunocompromised mice. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | CaOv-4; CaOV-4; CAOV-4; CAOV4; Caov4 |
| Species | Human |
| Cat.No | ABC-TC0115 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Growth Mode | Adherent |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Ovary |
| Disease | Adenocarinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Ovarian Cancer Cell Lines |
Caov-4 is a well-established in vitro model for studying epithelial ovarian cancer biology, drug sensitivity, and mechanisms of chemoresistance. It is particularly relevant for screening compounds targeting non-hormone-responsive ovarian tumors and for investigating TP53-related oncogenic pathways. Caov-4 also supports translational studies involving apoptosis, cell cycle regulation, and biomarker discovery in serous ovarian adenocarcinoma.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
